Association Between Markers of Vulnerability for Cannabis-Related Harms and Source of Supply: Secondary Analysis of a Representative Population Survey.


Journal

Canadian journal of psychiatry. Revue canadienne de psychiatrie
ISSN: 1497-0015
Titre abrégé: Can J Psychiatry
Pays: United States
ID NLM: 7904187

Informations de publication

Date de publication:
02 2023
Historique:
pubmed: 29 9 2022
medline: 11 2 2023
entrez: 28 9 2022
Statut: ppublish

Résumé

In 2018, the sale of non-medical cannabis was authorized in the province of Quebec in Canada, within a public monopoly under the Société Québécoise du Cannabis (SQDC). The objective of this study was to offer a description of the cannabis-using population regarding the sources of cannabis supply and to explore whether at-risk individuals are purchasing cannabis at SQDC. We used data from a cross-sectional, representative population survey (age >18 years, The vulnerability profiles of SQDC consumers (47.8%) and those acquiring their cannabis elsewhere (52.2%) were similar in terms of frequency of cannabis use (adjusted odds ratio [aOR] = 0.46; 95% confidence interval [CI] = 0.12-1.67), motivation to use (aOR = 0.62; 95% CI = 0.16-2.46), concomitant consumption of other substances (aOR = 0.80; 95% CI = 0.14-4.75), cannabis-impaired driving behaviours (aOR = 0.93; 95% CI = 0.26-3.36), psychological distress (aOR = 0.99; 95% CI = 0.26-3.79), and problematic cannabis use (aOR = 0.46; 95% CI = 0.13-1.64). However, SQDC consumers were more likely to be aware of the cannabinoid content of the product purchased compared to those who acquired their cannabis from other sources (aOR = 4.12; 95% CI = 1.10-15.40). No association was detected between the source of cannabis supply and potential vulnerability indicators of cannabis-related harms, but SQDC consumers were more aware of the cannabinoid content of the products purchased. These results suggest that the regulated government supply in Quebec is reaching a substantial portion of those with potential high vulnerability to harm. Whether this knowledge translates into a reduction in the negative consequences related to consumption is still to be determined.

Identifiants

pubmed: 36168206
doi: 10.1177/07067437221128470
pmc: PMC9923133
doi:

Substances chimiques

Cannabinoids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109-118

Références

Addiction. 2021 May;116(5):1000-1010
pubmed: 33160291
Am J Psychiatry. 2022 Feb;179(2):98-109
pubmed: 34875873
Tob Control. 2010 Oct;19(5):423-30
pubmed: 20876078
Arch Intern Med. 2007 Feb 12;167(3):221-8
pubmed: 17296876
Am J Public Health. 2014 Jun;104(6):1021-8
pubmed: 24825201
Brain. 2012 Jul;135(Pt 7):2245-55
pubmed: 22669080
CMAJ. 2017 Jul 24;189(29):E971-E972
pubmed: 28739851
J Stud Alcohol Drugs. 2011 Jan;72(1):86-95
pubmed: 21138715
Addict Behav Rep. 2019 May 10;10:100189
pubmed: 31193263
Addict Behav. 2019 Dec;99:106102
pubmed: 31473571
J Med Toxicol. 2017 Mar;13(1):71-87
pubmed: 28000146
PLoS One. 2013 Oct 24;8(10):e76635
pubmed: 24204649
Schizophr Bull. 2016 Sep;42(5):1262-9
pubmed: 26884547
Addiction. 2016 Apr;111(4):653-62
pubmed: 26598973
Drug Alcohol Depend. 2021 Aug 1;225:108794
pubmed: 34098382
Br J Clin Pharmacol. 2018 Nov;84(11):2468-2476
pubmed: 29953631
Int J Drug Policy. 2016 Aug;34:1-4
pubmed: 27198553
Psychol Addict Behav. 2015 Sep;29(3):627-32
pubmed: 25915689
Addiction. 2020 Jul;115(7):1207-1216
pubmed: 31606008
Arch Gen Psychiatry. 2003 Feb;60(2):184-9
pubmed: 12578436
J Public Health (Oxf). 2016 Mar;38(1):183-8
pubmed: 25630540
Lancet Public Health. 2017 Dec;2(12):e536-e537
pubmed: 29253435
Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):E2657-64
pubmed: 22927402
BMJ. 2012 Feb 09;344:e536
pubmed: 22323502
N Engl J Med. 2014 Jun 5;370(23):2219-27
pubmed: 24897085
Clin Pharmacol Ther. 2015 Jun;97(6):541-4
pubmed: 25677377
Cannabis Cannabinoid Res. 2020 Dec 15;5(4):274-278
pubmed: 33381640
Addiction. 2016 Oct;111(10):1764-73
pubmed: 27082374
J Public Health (Oxf). 2019 Jun 1;41(2):412-421
pubmed: 29860521
Biol Psychiatry. 2016 Apr 1;79(7):613-9
pubmed: 26903403
JAMA Psychiatry. 2020 Oct 1;77(10):1044-1051
pubmed: 32459328
Int J Methods Psychiatr Res. 2010 Jun;19 Suppl 1:4-22
pubmed: 20527002
Am J Psychiatry. 2016 Jun 1;173(6):588-99
pubmed: 26940807
Int J Drug Policy. 2022 Jan;99:103381
pubmed: 34465496
Nat Neurosci. 2020 May;23(5):600-610
pubmed: 32251385
Clin Pharmacol Ther. 2019 May;105(5):1139-1147
pubmed: 30703255

Auteurs

Sarah Drouin (S)

177460Research Center, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Department of Psychiatry and Addictology, 5622Université de Montréal, Montreal, QC, Canada.

Élie Rizkallah (É)

177460Research Center, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Department of Psychiatry and Addictology, 5622Université de Montréal, Montreal, QC, Canada.

Florence Conus (F)

25456Institut de la Statistique du Québec, Québec, QC, Canada.

Sarah Larney (S)

177460Research Center, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Department of Family Medicine, and Emergency Medicine, 5622Université de Montréal, Montreal, QC, Canada.

Navdeep Kaur (N)

177460Research Center, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.

Codjo Djignefa Djade (C)

177460Research Center, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.

Didier Jutras-Aswad (D)

177460Research Center, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC, Canada.
Department of Psychiatry and Addictology, 5622Université de Montréal, Montreal, QC, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH